Sanofi/Genzyme MS Drug Lemtrada Scores High Against Rebif
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Genzyme, a Sanofi company, set the bar high for its multiple sclerosis contender by stacking it up against Roche’s interferon beta-1a in Phase III trials and got the results it was looking for, with a filing set for this quarter.
You may also be interested in...
Lemtrada A Game Changer In MS, Genzyme Researchers Say
The paradigm shift long-lasting Lemtrada will excite, along with Aubagio’s gains since its launch in October, put Sanofi well on the road to its goal of multiple sclerosis leadership, Genzyme research execs say.
Sanofi's Oral Aubagio Jostles For Position In Multiple Sclerosis Market
FDA accepts filing for teriflunomide, but concerns about pregnancy risk in a young patient population and questions about comparative efficacy could limit market potential.
Top-Line Results For Sanofi/Genzyme's MS Drug Lemtrada Leave Investors Wanting More
Alemtuzumab scores a win in reducing relapse rates, but doesn't best interferon beta-1a at preventing disability in first of two crucial Phase III studies due to report this year.